N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
N/A N=98 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease
Crohn's Disease
Primary: Diagnostic Yield in Suspected Crohn's Patients (CE Prior to IC vs. IC and SBFT) — 97.3; 57.3 percentage of yield — p=<0.0001
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=121 Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease
Intestinal Disease · Inflammatory Bowel Disease · Crohn Disease
Primary: Normal vs Abnormal, Overall Impression — 42; 42; 72; 72 participants — p=1.0000
Phase 2 N=15 Use of Pancreatic Enzymes in Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Phase 3 N=49 Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
Parkinson's Disease
Primary: Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO) — 2; 12; 2; 9 participants — p=1.0
Phase 4 N=23 Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
N/A N=50 Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
Celiac Disease
Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Phase 2 N=75 PillCam® Platform With the PillCam Crohn's Disease Capsule
Crohn's Disease
Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…
Phase 4 N=8 Short Bowel Syndrome and Teduglutide Versus Placebo
Short Bowel Syndrome
Primary: Gastric Emptying Half-Time (T1/2) — 113; 106 minutes — p=0.74
N/A N=225 PillCam SB3 Capsule- Feasibility Study
Small/Large Bowel
Primary: Precentage of SB3 Images That Were Graded as Superior in Image Quality to SB2 by the Physicians — 98 percentage of cases
Phase 2 N=40 Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Crohn's Disease
Primary: • Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients — 62; 79 percentage of participants
Phase 4 N=24 Eluxadoline Bile Acid Malabsorption (BAM) Study
Irritable Bowel Syndrome With Diarrhea
Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale
N/A N=158 Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
Crohn Disease
Primary: Accuracy of CE Versus IC Plus MRE for Detecting Active Crohn's Disease (CD), by Visualizing the Small Bowel and Colon in Subjects With Know CD and Mucosal Disease. — 94…
Phase 2 N=8 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Phase 2 N=9 Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Short Bowel Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) — 9; 5; 3; 1 Participants
Phase 2 N=10 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Phase 2 N=78 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Small Bowel Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 24 — 25.0; 25.0; 16.7 percentage of participants